Clinical Trial Update: Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update on using low-dose dasatinib as first-line therapy for chronic myeloid leukemia, with the trial's current status listed as unknow…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Hospital Universitario Dr. Jose E. Gonzalez | Conditions: Chronic Myelogenous Leukemia | Phase 4 | Status: UNKNOWN